8Kim S J, Bae SN, Kim JH, et al. Effect of multiagent chemotherapy and indepent risk in the treatment of high-risk GTT-25years experiences of KRI-TRD. Int J Gynaecol Obstet, 1998, 60[Suppl 1]: S85-96.
9Bower M, Newlands ES, Holden L, et al. EMA/CO for high risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol, 1997,15(7): 2636-2643.
10Kim SJ, Bae SN, Kim JH, et al. Risk factors for prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Obstet Oncol, 1998,71(2): 247-253.
5Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high - risk gestation- al trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors, J Clin Oncol. 2000,18(4) :854 - 859.
6Bower M,Newlands ES, Holder L, et al. EMA/Co for high risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol, 1997,15970:2636 - 2643.
7Kim SJ, Bae SN, Kim JH, et al. Risk factors for prediction of treatment failure in festational trophoblastic tumors treated with EMA/CO regimen. Obstet Oncol, 1998,71 (2) :247 - 253.
8Cotter TG, Glynn JM, Escheverri F, et al. The induction of apoptosis in cells of the immune system by cytotxic stimuli [ J ]. Sem Immunol, 1992,4 (6) : 399-405.
9Donaldson KL, Goolsby G, Kiener PA, et al. Activation of p34^cde2 coincident with Taxol-induced apoptosis [ J ]. Cell Growth Diff, 1994,5 (10) : 1041-1050.
10Smith DB, Holden L, Newlands ES, et al. Correlation between clinical staging (FIGO) and prognostic groups in gestational trophoblastic disease [ J ]. Br J Obstet Gynaecol, 1989,96 (7) :795-802.
